The humoral response against SARS-CoV-2 one month after vaccination in patients with multiple sclerosis (MS) may depend on the medicines used to treat their condition, Swiss researchers say.

While patients taking cladribine or teriflunomide appear to generate an appropriate response, there is a diminished or absent response in their peers treated with anti-CD20 therapies or sphingosine-1-phosphate (S1P) receptor modulators, they report.